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Astroglia are multifunctional cells which regulate neuroinflammation and maintain 
homeostasis within the brain. Astroglial α-synuclein-positive cytoplasmic accumulations have 
been shown postmortem in patients with Parkinson’s disease and therefore astroglia may play 
an important role in the initiation and progression of Parkinson’s disease. The imidazoline 2 
binding sites are expressed on activated astroglia in the cortex, hippocampus, basal ganglia and 
brainstem; therefore, by measuring imidazoline 2 binding site levels we can indirectly evaluate 
astrogliosis in Parkinson’s disease patients. Here, we aimed to evaluate the role of astroglia 
activation in vivo in patients with Parkinson’s disease using [11C]BU99008 PET, a novel 
radioligand with high specificity and selectivity for imidazoline 2 binding sites. Twenty-two 
patients with Parkinson’s disease and 14 healthy controls underwent 3T MRI and a 120 min 
[11C]BU99008 PET scan with volume of distribution (VT) estimated using a two-tissue 
compartmental model with a metabolite corrected arterial plasma input function. Parkinson’s 
disease patients were stratified into early (n=8) and moderate/advanced (n=14) groups 
according to disease stage. In early Parkinson’s disease, increased [11C]BU99008 VT uptake 
was observed in frontal (P=0.022), temporal (P=0.02), parietal (P=0.026) and occipital 
(P=0.047) cortical regions compared with healthy controls. The greatest [11C]BU99008 VT 
increase in early Parkinson’s patients was observed in the brainstem (52%; P=0.018). In 
moderate/advanced Parkinson’s patients, loss of [11C]BU99008 VT was observed across frontal 
(P=0.002), temporal (P<0.001), parietal (P=0.039), occipital (P=0.024),  and insula (P<0.001) 
cortices; and in the subcortical regions of caudate (P<0.001), putamen (P<0.001) and thalamus 
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(P<0.001); and in the brainstem (P=0.018) compared with healthy controls. In Parkinson’s 
patients, loss of [11C]BU99008 VT in cortical regions, striatum, thalamus and brainstem 
correlated with longer disease duration (P<0.05) and higher disease burden scores, measured 
with Movement Disorder Society Unified Parkinson’s Disease Rating Scale (P<0.05). In the 
subgroup of moderate/advanced Parkinson’s patients, loss of [11C]BU99008 VT in the frontal 
(r=0.79; P=0.001), temporal (r=0.74; P=0.002) and parietal (r=0.89; P<0.001) cortex 
correlated with global cognitive impairment. This study demonstrates in vivo the role of 
astroglia in the initiation and progression of Parkinson’s disease. Reactive astroglia observed 
early in Parkinson’s disease could reflect a neuroprotective compensatory mechanisms and 
pro-inflammatory upregulation in response to α-synuclein accumulation. However, as the 
disease progresses and significant neurodegeneration occurs, astroglia lose their reactive 






Astroglia play a pivotal role in synaptic plasticity, neuroprotection and regulation of the blood-
brain barrier; as well as maintaining metabolic and ionic homeostasis and providing trophic 
support for surrounding neurons (Maragakis and Rothstein, 2001; Volterra and Meldolesi, 
2005; Rodriguez et al., 2009). Although astroglia are not strictly immune cells, they contribute 
together with microglia to the modulation of the innate and chronic immune brain response 
(Maragakis and Rothstein, 2006). When activated, astroglia change their morphology from a 
so-called surveying state to an activated state by enlarging their cell body and thickening their 
processes. Astroglial activation is characterized by the upregulation of intermediate filament 
proteins, such as the glial fibrillary acidic protein. Imidazoline 2 binding sites (I2BS), localised 
in the outer membrane of mitochondria in glial cells (Parini et al., 1996), have been shown to 
regulate the expression of glial fibrillary acidic protein (Sastre and Garcia-Sevilla, 1993). 
Preclinical studies showed rats treated with specific imidazoline antagonists induced parallel 
increases in I2BS and glial fibrillary acidic protein  (Garcia-Sevilla et al., 1999); indicating a 
direct physiological role for I2BS in the regulation of glial fibrillary acidic protein levels, and 
a link between I2BS and neuroinflammation (Head, 1998; Head and Mayorov, 2006). I2BS are 
expressed on reactive astroglia in the cortex, hippocampus, basal ganglia and brainstem (De 
Vos et al., 1991; De Vos et al., 1994). Therefore, the quantification of I2BS could be a useful 
indirect marker of reactive astroglia in vivo. Astroglia exert neuroprotective functions by 
clearing excess glutamate from the extracellular space via the glutamate transporter-1 to protect 
against excitotoxicity (Maragakis and Rothstein, 2001), suggesting that astroglia dysfunction 
and loss of this neuroprotective function may be particularly relevant to neuronal loss in 
neurodegeneration disorders.  
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In Parkinson’s disease, neuroinflammation in the substantia nigra pars compacta, including the 
presence of reactive astrogliosis was originally hypothesised as a downstream response arising 
as a consequence of dopaminergic neuronal death (Miklossy et al., 2006; Koprich et al., 2008). 
Accumulating evidence suggests that activated astroglia may play a key role early in the 
pathophysiology of Parkinson’s disease. Elevated levels of glial fibrillary acidic protein, which 
is regulated by I2BS, has been reported in the cerebrospinal fluid of early Parkinson’s patients 
suggesting the presence of astrogliosis early in the course of disease pathology (Sussmuth et 
al., 2010). It has been suggested that altered α-synuclein, released by axon terminals, is taken 
up by astroglial cells surrounding the synapses (Braak et al., 2007), supporting the hypothesis 
of neuron-to-astroglia propagation of α-synuclein (Lee et al., 2010). Moreover, a recent study 
provides evidence for the transmission of pathogenic α-synuclein from astrocytes to neurons 
(di Domenico et al., 2019). Thus, the accumulation of α-synuclein in astroglial cells, prior to 
neuronal loss in the substantia nigra pars compacta, may function as a key factor in the initiation 
and progression of Parkinson’s disease (Halliday and Stevens, 2011). The upregulation of 
reactive astroglia, expressing I2BS, could be an early neuroprotective phenomenon, in response 
in the accumulation of α-synuclein, in the pathophysiology of Parkinson’s disease. However, 
the role of reactive astroglia in Parkinson’s disease has not been in studied in vivo.   
 
The novel PET radioligand [11C]BU99008 has high specificity and selectivity for I2BS, which 
is expressed on reactive astroglia (Tyacke et al., 2012; Parker et al., 2014; Tyacke et al., 2018); 
therefore, providing an invaluable tool to elucidate the role of astroglial activation in 
Parkinson’s disease pathophysiology and its relationship with disease stage and burden, and 
symptom severity. Here, we investigated the role of reactive astroglia in vivo in early and 
moderate/advanced patients with Parkinson’s disease using [11C]BU99008 PET imaging.  
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MATERIALS AND METHODS 
Participants 
Twenty-two patients diagnosed with idiopathic Parkinson’s disease according to the UK Brain 
Bank criteria were recruited from specialist Movement Disorders clinics at King’s College 
Hospital NHS Foundation Trust, London, UK (Table 1). Fourteen healthy individuals with no 
history of neurological or psychiatric disorders served as the control group. Examples of 
specific exclusion criteria for all participants included (1) alcohol or drug dependency or abuse; 
(2) contraindication for PET or MRI scanning; (3) use of medications with known actions on 
I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, 
clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, 
methyldopa, fadolmidine, dexmedetomidine); and (4) a history of other neurological or 
psychiatric disorders. Imidazoline-2 receptors have been implicated to play a role in 
neuropathic pain, with studies showing Imidazoline-2 receptor ligands increasing the analgesic 
effects of opioids in chronic and persistent pain (Jett et al., 1999; Li and Zhang, 2011; Li et al., 
2014; Li, 2017). Therefore, participants with the presence of neuropathic pain were excluded 
from the study. All participants had adequate visual and auditory acuity to complete the 
psychological testing. Parkinson’s disease patients who were receiving Parkinson’s drugs 
stopped any dopaminergic medications 24 hours before the scans, and had imaging in the 
practically defined OFF state, and clinical assessments in both OFF and ON states. All 
participants screened successfully to undertake PET and MRI scanning under scanning safety 
criteria (http://www.mrisafety.com; 
https://www.gov.uk/government/publications/arsac-notes-for-guidance). The study was 
approved by the institutional review boards and the research ethics committee. Permission to 
use radioactive substances was obtained by the Radioactive Substances Advisory Committee, 
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Department of Health and Social Care, United Kingdom. Written informed consent was 
obtained from all study participants in accordance with the Declaration of Helsinki. 
 
Clinical assessments and Stratification  
Global Parkinson’s disease clinical burden was assessed with the Movement Disorders Society 
(MDS) Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), including MDS-UPDRS-
III for the examination of motor symptoms, MDS-UPDRS-II for motor experiences of daily 
living and MDS-UPDRS-I for non-motor experiences of daily living. Disease severity was also 
classed with the Hoehn and Yahr (H&Y) scale. Daily dopamine agonist equivalent dose 
(LEDDA) and daily levodopa equivalent dose (LEDL-DOPA) unit calculations were based on 
theoretical equivalence to levodopa as described previously (Politis et al., 2010). 
 
Parkinson’s disease patients were stratified according to disease stage into early (n=8) and 
moderate/advanced (n=14) Parkinson’s disease subgroups in order to investigate I2BS level in 
different clinical stages of Parkinson’s disease (Table 1). Early Parkinson’s patients had less 
than 5 years of disease duration, average MDS-UPDRS-III OFF of 13.63 (±5.10), average 
H&Y OFF of 1.25 (±0.71). Five early Parkinson’s patients were naïve to treatment for 
Parkinson’s symptoms (de novo) and 3 early Parkinson’s patients were taking dopamine 
agonists for less than 3 months but not on levodopa treatment, and had mean daily LEDDA of 
53.38 mg (±84.14). Moderate/advanced Parkinson’s patients had more than 6 years of disease 
duration, average MDS-UPDRS-III OFF of 44.93 (±18.49), average H&Y OFF of 2.50 (±1.40), 




Global cognitive function was assessed with the Mini Mental Status Examination (MMSE) and 
the Montreal Cognitive Assessment (MoCA). Olfactory function was assessed with the 
University of Pennsylvania Smell Identification Test (UPSIT). Total non-motor symptom 
burden was assessed with the Non-motor Symptom Scale (NMSS). Depression levels were 
assessed with the Beck Depression Inventory-II (BDI-II) and autonomic symptoms with the 
Scales for Outcomes in Parkinson's disease–Autonomic (SCOPA-AUT). Pain was assessed 
with the King’s Pain Scale (Table 1).  
 
Imaging assessments 
Participants underwent PET and MR imaging, which was performed at Invicro LLC, London, 
UK. Participants were scanned on a Siemens Biograph Hi-Rez 6 PET-CT scanner (Erlangen, 
Germany). A mean dose of 316.56 MBq (±13.98) [11C]BU99008 was administered 
intravenously as a slow bolus injection over 20s.  
 
Dynamic emission data were acquired continuously for 120 minutes following the injection of 
[11C]BU99008. The dynamic images were reconstructed into 26 frames (8 x 15 s, 3 x 60 s, 5 x 
120 s, 5 x 300 s, and 5 x 600 s), using a filtered back projection algorithm (direct inversion 
Fourier transform) with a 128 matrix, zoom of 2.6 producing images with isotropic voxel size 
of 2 x 2 x 2 mm3, and smoothed with a transaxial Gaussian filter of 5 mm. Blood sampling was 
performed for [11C]BU99008 through an arterial line inserted in the radial artery to generate 
arterial plasma input data. For the initial 15 minutes radioactivity levels in blood was 
continuously measured through an automatic blood sampling system at 5ml/min, followed by 
samples at 5, 10, 15, 20, 25, 30, 40, 50, 60, 80, 100, 110 and 120 min during the scan. Plasma 
samples and the fraction of unchanged radioligand was determined according to previously 
described procedures (Tyacke et al., 2018). There were no differences in the plasma free 
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fraction of [11C]BU99008 between the groups of Parkinson’s disease patients and healthy 
controls. 
 
MRI scans were acquired with a 32-channel head coil on a Siemens Magnetom MAGNETOM 
TrioTim syngo MR B17 (Erlangen, Germany), 3T MRI scanner. MRI acquisition included a 
T1-weighted Magnetization Prepared Rapid Gradient Echo sequence [MPRAGE; time 
repetition = 2300 ms; time echo = 2.98 ms, flip angle of 9°, time to inversion = 900 ms; matrix 
= 240 x 256 x 160; voxel size = 1.0 mm x 1.0 mm x 1.0 mm; slice thickness 1.0 mm]. 
 
Imaging data analysis 
PET data analysis 
The Molecular Imaging and Kinetic Analysis Toolbox software package (MIAKATTM: 
www.miakat.org), implemented in MATLAB® (The Mathworks, Natick, MA, USA) was used 
to carry out image processing and kinetic modelling. MIAKAT™ combines in-house code with 
wrappers for FMRIB Software Library (FSL, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/) and 
Statistical Parametric Mapping (SPM, http://www.fil.ion.ucl.ac.uk/spm/) commands in order 
to provide state-of-the-art functionality within a coherent analysis framework. Individual PET 
frames were corrected for head motion using frame-by-frame rigid registration using frame 16, 
with high signal-to-noise ratio, as reference. The MIAKATTM processing pipeline allows for 
modelling of input function data, regional sampling of PET data and creation of motion-
corrected time-activity-curves. Parent plasma input functions were derived from the arterial 
blood measurements, the whole‐blood data corrected for plasma and metabolite fractions using 
sigmoid models, and interpolated with a triexponential function (Tyacke et al., 2018). The 
arterial blood samples were used to determine a plasm input function which enabled modelling 
of the time-activity-curves and estimation of the total volume of distribution (VT) using the 
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two-tissue compartment model (2TCM), with fixed 5% blood volume, which has been shown 
as the most appropriate and reliable model for [11C]BU99008. 
 
Partial Volume Correction 
To account for atrophy and volumetric loss on [11C]BU99008 VT measures regions of interest 
were segmented with grey matter mask, generated by segmenting subjects’ MRI, to extract 
[11C]BU99008 VT from regions of interest within the grey matter. Furthermore, partial volume 
correction was performed using on 3-compartment (grey matter, white matter and CSF) 
segmentation method (Meltzer et al., 1990; Muller-Gartner et al., 1992). [11C]BU99008 VT 
values were considered with and without partial volume correction. 
 
Region-of-interest analysis  
The multi-atlas propagation with enhanced registration (MAPER) was used to define region of 
interests (Heckemann et al., 2010). MRI scans were automatically segmented using the 
MAPER approach into 95 anatomic regions. This robust technique improves the quality of 
multi-atlas based automatic whole-brain segmentations (Heckemann et al., 2010), and is 
applicable even to subjects with significant cortical atrophy and ventriculomegaly. The output 
object maps were visually checked independently by two reviewers to ensure accurate 
segmentation based on each subjects’ structural MRI. Motion-corrected time-activity curves 
were generated for the regional quantification of [11C]BU99008 PET data.  
 
MRI volumetric FreeSurfer analysis 
FreeSurfer image analysis suite was used to derive measures of cortical thickness and deep 
grey matter nuclei volume. Cortical thickness was measured as the distance from the grey and 
white matter boundary to the corresponding pial surface. Reconstructed data sets were visually 
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inspected to ensure accuracy of registration, skull stripping, segmentation, and cortical surface 
reconstruction. Subcortical structure volumes were derived by automated procedures, which 
automatically assign a neuroanatomical label to each voxel in an MRI volume based on 
probabilistic information automatically estimated from a manually labelled training set (Fischl 
et al., 2002). All individual nuclei volumes were normalised for total intracranial volume 
automatically generated by FreeSufer (Malone et al., 2015).  
 
Voxel-based morphometry  
 
Images were segmented into grey matter, white matter and CSF tissue classes using the 
statistical parametric mapping (SPM) version 12 software package (Wellcome Department of 
Imaging Neuroscience, London, UK). Grey and white matter images were normalized to a grey 
and white matter population template, generated from the complete image set using the 
diffeomorphic anatomical registration using exponentiated lie-algebra (DARTEL) registration 
method (Ashburner, 2007). This non-linear warping technique minimizes between-subject 
structural variations. All images were checked following spatial normalization to ensure 
registration accuracy. The final voxel resolution was 1·0 mm x 1·0 mm x 1·0 mm. Spatially 
normalized images were modulated by the Jacobian determinants so that intensities represent 
the amount of deformation needed to normalize the images, and then smoothed with an 8 mm 
full-width at half-maximum Gaussian kernel. Voxel-based multiple regression analysis (based 
on the general linear model) was carried out using SPM12 with voxel-wise grey and white 
matter volumes as the dependent variables. Age and gender were added as nuisance covariates. 
The threshold for statistical significance was set at P<0·05 after family wise error (FWE) 




Statistical analysis and graph illustration were performed with SPSS (version 20 Chicago, 
Illinois, USA) and GraphPad Prism (version 6.0c) for MAC OS X, respectively. For all 
variables, variance homogeneity and Gaussianity were tested with Bartlett and Kolmogorov-
Smirnov tests. We proceeded with parametric tests as our imaging and clinical data were 
normally distributed. Multivariate analysis of variance (MANOVA) was used to assess group 
differences in clinical measures and multivariate analysis of covariance (MANCOVA) with 
age, gender, LEDDA, LEDL-DOPA, BDI-II and King’s pain scale as covariates was used to assess 
group differences in [11C]BU99008 VT values. If the overall multivariate test was significant, 
P values for each variable were calculated following Bonferroni’s multiple comparisons test. 
We interrogated correlations between [11C]BU99008 VT values and clinical data using a 
covariate-adjusted spearman’s rank correlation, with age, gender, LEDDA, LEDL-DOPA, BDI-II 
and King’s pain scale as covariates. We set the false discovery rate cut-off at 0.05. All data are 





There was no difference in age between early Parkinson’s disease patients (P=0.64) and healthy 
controls, and between early Parkinson’s patients and moderate/advanced Parkinson’s patients 
(P=0.094). However, the moderate/advanced Parkinson’s disease patients were older 
compared with the healthy controls (P=0.036); therefore, age was included as covariate in all 
the statistical analysis. Compared with early Parkinson’s disease patients, moderate/advanced 
Parkinson’s disease patients had longer disease duration (P<0.001), higher total daily LED 
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intake (P=0.036), greater burden of motor symptoms (MDS-UPDRS-III OFF: P<0.0001; H&Y 
OFF: P=0.012) and greater total disease burden (MDS-UPDRS Total OFF: P=0.001; Table 1). 
 
The moderate/advanced Parkinson’s disease patients had greater olfactory dysfunction 
compared with the cohort of early Parkinson’s disease patients (UPSIT: P=0.003); while global 
burden of non-motor symptoms (NMSS Total: P=0.54), depression levels (BDI-II: P=0.23), 
pain (King’s Pain Scale: P=0.13), autonomic dysfunction (SCOPA-AUT: P=0.21) and global 
cognitive function (MMSE: P=0.92; MoCA: P=0.24) were not significantly different between 
early and moderate/advanced Parkinson’s disease patients (Table 1). 
 
Region-of-interest based analysis 
Multivariate analysis across the three groups revealed significant differences in cortical 
[11C]BU99008 VT uptake (F(10,42)=14.85, P<0.001, Wilks' Λ=0.049) after covarying for age, 
gender, LEDDA, LEDL-DOPA, BDI-II and King’s pain scale. Between the three groups, 
significant differences in [11C]BU99008 VT were observed in the frontal (F(2,25)=17.81, 
P<0.001), parietal (F(2,25)=12.80, P<0.001), temporal (F(2,25)=20.37, P<0.001), occipital 
(F(2,25)=11.73, P<0.001), and insula (F(2,25)=19.25, P<0.001), cortices after covarying for 
age, gender, LEDDA, LEDL-DOPA, BDI-II and King’s pain scale. 
 
[11C]BU99008 VT findings in early Parkinson’s disease patients 
In early Parkinson’s patients, increased [11C]BU99008 VT uptake (following partial volume 
correction) was observed in frontal cortical regions, including the straight frontal gyrus 
(P=0.014), precentral gyrus (P=0.023, uncorrected), inferior (P=0.018) and superior (P=0.05) 
frontal gyrus, medial (P=0.017) and lateral (P=0.10), anterior (P=0.024), and posterior 
(P=0.025, uncorrected) orbital gyrus; temporal cortical regions, including the superior 
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temporal gyrus middle part (P=0.031, uncorrected), middle and inferior temporal gyrus 
(P=0.037, uncorrected), posterior temporal lobe (P=0.045, uncorrected), anterior temporal lobe 
lateral part (P=0.025, uncorrected) and the anterior temporal lobe medial part (P=0.045, 
uncorrected); parietal cortical regions including the supramarginal gyrus (P=0.039), 
postcentral gyrus (P=0.016), superior parietal gyrus (P=0.014) and the angular gyrus (P=0.02, 
uncorrected); and occipital cortical regions including the cuneus cortex (P=0.029), the lingual 
gyrus (P=0.05, uncorrected) and the remaining occipital lobe (P=0.029, uncorrected; Figures 
1 & 2). Early Parkinson’s disease patients showed also increased [11C]BU99008 VT uptake in 
the anterior cingulate gyrus (P=0.036) and in the brainstem (P=0.018). No differences were 
found in the insula cortex or in subcortical regions in early Parkinson’s disease compared with 
healthy controls. The greatest increase in [11C]BU99008 VT was observed in the brainstem 
showing approximately 52% increase in early Parkinson’s disease compared with healthy 
controls (Table 2).  
 
[11C]BU99008 VT findings in moderate/advanced Parkinson’s disease patients 
In moderate/advanced Parkinson’s disease patients, global decrease of [11C]BU99008 VT 
uptake was observed across frontal (P=0.002), temporal (P<0.001), parietal (P=0.039), 
occipital (P=0.024), insular (P<0.001) cortices and the anterior (P=0.008) and posterior 
(P=0.003) cingulate compared with healthy controls (Figures 1 & 2). Within subcortical 
regions, loss of [11C]BU99008 VT was observed in the caudate (P<0.001), putamen (P<0.001), 
thalamus (P<0.001), and in the brainstem (P=0.018; Table 2). 
 
We also evaluated [11C]BU99008 VT data without partial volume error correction to identity 
any differences in the results. Without partial volume correction, [11C]BU99008 VT was 
increased in the frontal (P=0.035), temporal (P=0.048) and parietal (P=0.015) cortex and in the 
brainstem (P=0.045) in early Parkinson’s disease patients; and decreased in the frontal 
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(P<0.001), temporal (P<0.001), parietal (P<0.001), insula (P<0.001) and occipital (P<0.001) 
cortex and in caudate (P<0.001), putamen (P<0.001), thalamus (P<0.001) and brainstem 
(P<0.001) in moderate/advanced Parkinson’s disease patients compared with healthy controls 
(Table S1). With the exception of the occipital and cingulate cortex which came significant 
only after partial volume correction, the results without partial volume correction were 
consistent with findings after partial volume correction (Table 2).  
 
Correlations with clinical data 
Lower [11C]BU99008 VT values in the frontal (r=-0.64; P=0.001), temporal (r=-0.96; 
P<0.001), parietal (r=-0.59; P=0.007), occipital (r=-0.58; P=0.01) and insula (r=-0.60; 
P=0.006) cortices, and in the caudate (r=-0.63; P=0.004), putamen (r=-0.62; P=0.005), 
thalamus (r=-0.61; P=0.006) and brainstem (r=-0.59; P=0.004) correlated with longer disease 
duration in all Parkinson’s patients (Figure 3A). Lower [11C]BU99008 VT values in the frontal 
(r=-0.76; P<0.001), temporal (r=-0.61; P=0.003), parietal (r=-0.55; P=0.011), occipital (r=-
0.51; P=0.026) and insular (r=-0.56; P=0.009) cortices, and in the caudate (r=-0.59; P=0.006), 
putamen (r=-0.53; P=0.011), thalamus (r=-0.58; P=0.007) and brainstem (r=-0.59; P=0.004) 
correlated with higher total disease burden, measured with total MDS-UPDRS (Figure 3B). In 
the subgroup of moderate/advanced Parkinson’s patients, loss of [11C]BU99008 VT in the 
frontal (r=0.79; P=0.001), temporal (r=0.74; P=0.002) and parietal (r=0.87; P<0.001) cortices 
correlated with worse global cognitive scores as assessed with MoCA (Figure 3C). 
 
MRI volumetric analysis 
FreeSurfer analysis revealed no difference in cortical thickness between groups of Parkinson’s 
disease patients and healthy controls (Table S2). No differences in subcortical volumes were 
observed in basal ganglia regions or the hippocampus (Table S3). However, within the 
brainstem, moderate/advanced Parkinson’s disease patients showed significant volumetric loss 
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(P=0.035) and early Parkinson’s disease patients showed borderline volumetric loss (P=0.053) 
compared with healthy controls (Table S3). Whole brain voxel-based morphometry between 
groups of Parkinson’s disease patients and healthy controls revealed no volume changes at a 
voxel level in any brain region. To address potential issues of bias from volume loss, we applied 
partial volume correction and report all partial volume corrected [11C]BU99008 VT values.  
 
DISCUSSION 
In this study we used non-invasive [11C]BU99008 PET molecular imaging, a marker of I2BS, 
to evaluate astroglia pathology in vivo in patients with Parkinson’s disease. Our findings 
demonstrate increased expression of I2BS, reflecting reactive astrogliosis, in cortical areas and 
the brainstem of early Parkinson’s patients. However, in the moderate/advanced Parkinson’s 
cases I2BS expression was decreased in cortical and subcortical areas, reflecting loss of 
astroglia function as the disease advances and disease burden increases, and such loss in the 
cortical areas correlated with worse cognitive scores.  
 
In early Parkinson’s patients, we observed increased expression of I2BS in several frontal, 
temporal, parietal and occipital gyri, with the highest increases (52%) observed in the 
brainstem. Our findings are consistent with the hypothesis that reactive astrogliosis occurs in 
early stage Parkinson’s disease, possibly due to neuroprotective compensatory mechanisms 
and pro-inflammatory upregulation in response to α-synuclein accumulation (Halliday and 
Stevens, 2011; Barcia et al., 2012). Our findings are in line with preclinical studies which have 
demonstrated increased expression of interferon-γ receptors on astroglia, as well as tumour 
necrosis factor (TNF)-α immunoreactivity related to astrogliosis, suggesting that astroglial 
overactivation trigged by the accumulation of α-synuclein could play a crucial role in the 
initiation of pathophysiological processes in Parkinson’s disease (Halliday and Stevens, 2011; 
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Barcia et al., 2012). Astroglia containing α-synuclein are thought to be more widespread 
throughout the brain compared with Lewy bodies (Braak et al., 2007), which would explain 
the increased levels of I2BS, reflecting reactive astrogliosis, observed in the present study 
throughout the cortex and in the brainstem of early Parkinson’s patients. Astroglial cells can 
also activate microglial cells (Gu et al., 2010; Halliday and Stevens, 2011; Schmidt et al., 
2011), and vice versa with microglial activation inducing astrogliosis (Balasingam et al., 1996; 
Hanisch, 2002; Rohl et al., 2007). Increased microglial activation has been previously 
demonstrated in vivo with [11C]PK11195, [18F]FEPPA and [11C]DPA713 PET imaging, further 
supporting the role of neuroinflammation in Parkinson’s pathophysiology (Ouchi et al., 2005; 
Terada et al., 2016; Ghadery et al., 2017; Kang et al., 2018). Such evidence taken together 
with our findings, suggests that astroglia and microglia are likely key players in the 
pathophysiology of Parkinson’s disease.  
 
In moderate/advanced Parkinson’s patients we observed decreased expression of I2BS in 
frontal, temporal, parietal, occipital, and insula cortices, in the brainstem and in subcortical 
regions such as caudate, putamen and thalamus. This was an opposite phenomenon compared 
with the early Parkinson’s cases, and indicated loss of astroglia function as Parkinson’s disease 
progresses. Loss of astroglial function could reflect loss of neuroprotective mechanisms and 
increased neurotoxic effects associated with the presence of gradually increasing 
neurodegeneration processes (Maragakis and Rothstein, 2001; Gu et al., 2010). Reactive 
astroglia display a complex interplay between the neuroprotective and neurotoxic effects. In 
preclinical studies, the overexpression of the mutant α-synuclein in astroglial cells altered the 
normal function of astroglia, leading to reduced integrity of the blood-brain-barrier, a decreased 
homeostasis of extracellular glutamate and a significant loss of dopaminergic neurons in the 
midbrain (Gu et al., 2010). In post-mortem Parkinson’s brains, α-synuclein inclusions have 
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been reported within astroglia (Braak et al., 2007). Following chronic astrogliosis to clear 
extracellular α-synuclein, astroglia could degenerate and become inactivated. Astroglia also 
help to protect against excitotoxicity by clearing excess glutamate from the extracellular space 
via the glutamate transporter-1 (Maragakis and Rothstein, 2001). Gu and colleagues (2010) 
showed that the presence of increasing levels of α-synuclein in reactive astrocytes disrupts the 
normal functioning of astrocytes which is critical for maintaining the integrity of the blood-
brain barrier and homeostasis of extracellular glutamate. Therefore, reduced expression of 
proinflammatory cytokines, such as Interukein-1α, Interukein-1β, in response to increasing 
extracellular α-synuclein, in late stages of Parkinson’s disease, may not only compromise anti-
inflammatory functions of astrocytes, but also leave neurons more vulnerable to toxic insults. 
Moreover, progressive neurodegeneration has been shown to be related to astrocyte 
dysfunction and the expression of inflammatory molecules by astrocytes leading to microglial 
activation (Gu et al., 2010; Lee et al., 2010). It is likely that for astrocytes to function normally, 
they have to keep low levels of α-synuclein expression. However, astrocytes are less able to 
detoxify the excess α-synuclein, compared with microglia, due of their lower level of cathepsin 
D which has been shown to effectively degrade α-synuclein (Wootz et al., 2006; Qiao et al., 
2008; Cullen et al., 2009). A recent study provides direct evidence that astrocyte dysfunction 
can lead to PD-associated neurodegeneration through the impairment of chaperone-mediated 
autophagy in iPSC-derived astrocytes from PD patients compared with controls astrocytes (di 
Domenico et al., 2019). Therefore, as Parkinson’s disease progresses astroglial dysfunction, 
accompanied by increasing α-synuclein accumulation, loss of glial neuroprotective functions 
and increased excitotoxicity, could explain the gradual neuronal loss observed in Parkinson’s 
disease and the increasing disease burden. While there are multiple lines of evidence to support 
the loss of astroglia function, we cannot fully exclude the possibility that α-synuclein astrocytic 
inclusions might affect the expression of I2BS in the astrocytic membranes. Thus, further work 
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is required to fully elucidate the exact mechanisms underlying the loss of I2BS, measured with 
[11C]BU99008 PET. 
 
In line with the concept that astroglial pathology may have relevance to disease burden and 
clinical implications, our findings show that loss of I2BS expression correlated with longer 
disease duration and higher total MDS-UPDRS scores, which measures the global burden of 
the disease. Furthermore, in moderate/advanced Parkinson’s disease, loss of I2BS expression 
in cortical regions involved in cognitive function correlated with lower MoCA scores, which 
captures global cognitive impairment. These findings suggest that as Parkinson’s disease 
progresses, astroglial dysfunction, accompanied by loss of glial neuroprotective functions and 
increased excitotoxicity, has clinical relevance in the development of cognitive impairment and 
increasing global disease burden. Further studies are warranted, in a cohort of Parkinson’s 
disease patients with cognitive impairment to fully elucidate the role of I2BS in cognitive 
impairment. Pharmacological manipulation of astroglia function could potentially have a 
therapeutic role in the alleviation of Parkinson’s disease symptoms and might slow increasing 
disease burden. Larger longitudinal studies are required to confirm these findings.   
 
Similarly, to the M1/M2 phenotypes of microglia, astroglia also harbour different isoforms of 
reactivity (Paolicelli et al., 2011). A1 astroglia known as the neurotoxic phenotype, upregulate 
many classical complement cascade genes, such as C3, C4, C1r and C1s, which are destructive 
to synapses (Stevens et al., 2007; Liddelow et al., 2017). In contrast A2 astroglia, which is the 
neuroprotective phenotype, upregulate many neurotrophic factors, such as CLCF1, LIF and IL-
6, which promote the survival and growth of neurons as well as synaptic repair (Zamanian et 
al., 2012). Astroglial overactivation results in the release of pro-inflammatory cytokines, nitric 
oxide and reactive oxygen species which can have detrimental effects in chronic 
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neuroinflammation  (Neumann et al., 2002; Deshpande et al., 2005; Mizuno et al., 2005; Zhang 
et al., 2005; Qian and Flood, 2008; Dean et al., 2010; Lee et al., 2010; Qian et al., 2010). The 
majority of post-mortem studies in Parkinson’s brains focus in microgliosis and 
neuroinflammatory mediators while the literature in astroglia is less extensive. From 
pathological examinations, an increase in the number of astroglia, as well as in glial fibrillary 
acidic protein expression, has been observed in Parkinson’s disease (Damier et al., 1993; Braak 
et al., 2007). Recently, the A1 astroglia phenotype was reported in the substantia nigra of 
Parkinson’s brains (Liddelow et al., 2017). Therefore, the shift from an A2 to A1 phenotype 
could be important for disease progression. 
 
In post-mortem Parkinson’s disease brains, the density of GFAP-positive astrocytes has been 
shown to be inversely related to the magnitude of dopaminergic neuronal loss (Damier et al., 
1993). This suggests that dopaminergic neurons within areas where astrocytes have lost their 
function are more prone to degenerate. Furthermore, in Parkinson’s disease the severity of 
substantia nigra pars compacta dopaminergic neuronal loss correlated positively with the 
number of α-synuclein–positive inclusions within astrocytes in the substantia nigra pars 
compacta (Wakabayashi et al., 2000). Therefore, increasing accumulation of α-synuclein 
within astrocytes could subsequently result in loss of astroglia function and eventually neuronal 
death. While some post-mortem studies have reported a mild increase in the number of 
astrocytes these findings are not consistency observed (Forno et al., 1992; Mirza et al., 2000; 
Tong et al., 2015). The presence of the A1 astroglia phenotype in the substantia nigra of 
Parkinson’s disease brains suggests that astrocytes detected at post-mortem could display an 
A1 neurotoxic phenotype, with astrocytes shifting from an A2 to A1 phenotype in later stages 
of the disease (Stevens et al., 2007; Liddelow et al., 2017). While post-mortem studies provide 
important insights into pathological changes present at end stages of the disease, it is difficult 
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to disentangle from post-mortem studies alone if findings of increased I2BS levels is reflective 
of massive neuronal death and neurodegeneration occurring at the time of death or if these 
changes reflect a core disease mechanism in the pathophysiology of Parkinson’s disease and 
the extent to which they contribute to disease progression. This highlights the importance of 
PET imaging studies, with a specific marker for astroglia activation, which allow the 
investigation of molecular pathology in vivo in Parkinson’s disease patients.” 
 
It is important to note that I2BS are co-expressed with monoamine oxidase type B (Sastre and 
Garcia-Sevilla, 1993)  however the binding site for the I2BS is distinct from that of monoamine 
oxidase type B (McDonald et al., 2010).  Increased monoamine oxidase type B activity has 
also been linked with astrogliosis (Oreland and Gottfries, 1986; Ekblom et al., 1993). 
Specifically, upon brain insult monoamine oxidase type B levels increase through reactive 
astroglia inducing the expression of several cytokines, including IL-1, IL-6, and TNF-a 
(Ekblom et al., 1994; Quintana et al., 2005). Taken together, these data suggest that I2BS are 
also linked with neuroinflammatory response through their high affinity with increased 
monoamine oxidase type B activation and reactive astroglia response. Therefore, it could be 
argued that changes in I2BS levels measured here may reflect changes in monoamine oxidase 
type B. However, a series of blocking studies in vivo have confirmed the selectivity and 
specificity of the [11C]BU99008 radioligand for I2BS on astroglia (Parker et al., 2014; Tyacke 
et al., 2018). To validate the selectivity of [11C]BU99008 for I2BS, a blocking study in rhesus 
monkeys showed that blocking with monoamine oxidase inhibitors had no significant effects 
on [11C]BU99008 signal while blocking I2BS inhibitor exhibited a dose-dependent decrease in 
signal (Parker et al., 2014). A recent blocking study in healthy controls, demonstrated no signal 
reduction following combined monoamine oxidase type A and B inhibition while treatment 
with an I2BS inhibitor resulted in loss of [
11C]BU99008 signal (Tyacke et al., 2018). Combined 
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these studies support the use of [11C]BU99008 as a suitable radioligand for the quantification 
of I2BS as a marker of astroglia activation in vivo with high specificity and selectivity for I2BS.  
 
Age, gender, depression, pain and dopaminergic medication are potential confounding factors 
which could influence I2BS levels. Therefore, to control for these we included as co-variates 
age, gender, LEDDA, LEDL-DOPA, depression and pain in all statistical analysis. To address 
potential issues of bias from volume loss, we applied partial volume correction to 
[11C]BU99008 VT values. While, we found volumetric loss of approximately 7% in the 
brainstem in early and moderate/advanced Parkinson’s patients, this was much less than the 
52% increase and 48% decrease in [11C]BU99008 VT in early and moderate/advanced 
Parkinson’s disease patients, respectively. Given the percentage change of [11C]BU99008 VT 
in the brainstem is greater than the degree of brainstem atrophy, it is unlikely that volumetric 
loss was driving the change in [11C]BU99008 VT. Furthermore, the high levels of activated 
astroglia before pronounced atrophy becomes evident may suggest that reactive astrogliosis 
occurs prior to manifested neuronal loss. To our knowledge, this is the first report 
demonstrating reactive astrogliosis is present in early Parkinson’s disease with loss of astroglia 
function as the disease advances and disease burden increases in moderate to advanced disease 
stages, using [11C]BU99008 PET in vivo. Therefore, further studies are warranted to confirm 
these findings and to further explore the association between loss of I2BS and cognitive decline 
in a larger cohort of Parkinson’s patients with cognitive impairment.  
 
In conclusion, our findings provide novel knowledge and evidence in vivo in patients for the 
role of astroglia pathology in Parkinson’s disease. The early phenomenon of increased levels 
of I2BS reflecting cortical and brainstem reactive astrogliosis is intriguing and warrants further 
investigation in cohorts at risk for development of Parkinson’s disease including those with 
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idiopathic rapid eye movement (REM) behavioural disorder and asymptomatic/premotor 
carriers of parkinsonism related mutations. Longitudinal data would also be of great value in 
order to assess the potential of [11C]BU99008 PET as a marker of disease progression.  
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Figure 1 Bar graphs showing regional total distribution volume (VT) in [
11C]BU99008 in early 
and moderate/advanced Parkinson’s disease patients compared with healthy controls in cortical 
regions (A) and subcortical regions and the brainstem (B). Increased [11C]BU99008 VT uptake 
is observed in early Parkinson’s disease, with greatest increase in the brainstem, while in 
advanced disease stages there is a global loss of [11C]BU99008 VT. Partial volume corrected 
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[11C]BU99008 VT expressed in cm
3/mL. *P<0.05 Bonferroni corrected for multiple-
comparisons compared with healthy controls.  
 
Figure 2 [11C]BU99008 standardized uptake value (SUV) images showing increased I2BS in 
early Parkinson’s disease patients while moderate/advanced Parkinson’s disease patients show 
global loss of I2BS compared with healthy controls. Axial, sagittal and coronal (MNI co-
ordinates: X= 43; Y = 46; Z = 39) [11C]BU99008 SUV images from a representative healthy 
control (A; 65 year old male), early Parkinson’s’ disease patient (B; 60 year old female; disease 
duration 2 years; MDS-UPDRS-III=11; MoCA=28) and moderate/advanced Parkinson’s disease 
patient (C; 63 year old male; disease duration 16 years; MDS-UPDRS-III=69; MoCA=24).  
 
Figure 3 Loss of [11C]BU99008 VT correlated with longer disease duration (A) and high total 
disease burden (MDS-UPDRS Total; B) in Parkinson’s disease patients. In the subgroup of 
moderate/advanced Parkinson’s patients, loss of [11C]BU99008 VT correlated with global 
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